Arctic Bioscience Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Christer Valderhaug

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	0.06%
Management average tenure	6.2yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

CEO

Christer Valderhaug (52 yo)

no data

Tenure

Mr. Christer L. Valderhaug serves as Chief Executive Officer at Arctic Bioscience AS. He serves as Senior Advisor at Converto Holding As (formerly known as Converto AS) since November 2016. He came from th...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Harald Nordal	Co-Founder & Chairman	9.1yrs	no data	0.079% € 3.5k
Christer Valderhaug	Chief Executive Officer	no data	no data	0.055% € 2.4k
Hogne Hallaraker	Founder & Chief Scientific Officer	6.6yrs	no data	1.83% € 80.7k
Jone Slinning	Chief Financial Officer	2.6yrs	no data	0.052% € 2.3k
Per Sæbo	Chief Operating Officer	12.3yrs	no data	0.090% € 4.0k
Daniele Mancinelli	Chief Technical Officer	12.3yrs	no data	0.0079% € 347.0
Steffen Eidal	Senior Vice President of Sales & Marketing	2.6yrs	no data	no data
Yuming Feng	Executive Vice President of Global Business Development	6.2yrs	no data	no data
Runhild Gammelsæter	Global Medical Director	5.3yrs	no data	0.14% € 6.0k

6.2yrs

Average Tenure

57yo

Average Age

Experienced Management: 9TD's management team is seasoned and experienced (6.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Harald Nordal	Co-Founder & Chairman	9.1yrs	no data	0.079% € 3.5k
Jostein Dalland	Independent Board Member	4.7yrs	no data	no data
Tore Andreas Tonseth	Board Member	3.8yrs	no data	no data
Asbjorn Solevagseide	Board Member	5.6yrs	no data	no data
Jan Vartdal	Board Member	9.1yrs	no data	4.1% € 180.6k
Per Eggesbo	Board Member	8.8yrs	no data	no data
Hu Cao	Board Member	3.8yrs	no data	no data
Marita Holstad	Director	3.8yrs	no data	no data

5.1yrs

Average Tenure

58yo

Average Age

Experienced Board: 9TD's board of directors are considered experienced (5.1 years average tenure).

Arctic Bioscience Management

Management criteria checks 2/4

Key information

Recent management updates

Global Medical Director recently bought €15k worth of stock

Chief Executive Officer recently bought €28k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Recent updates

Arctic Bioscience AS Provides Revenue Guidance for the Year 2024

New major risk - Market cap size

Arctic Bioscience Announces Top-Line Results from Phase 2b HeROPA Study

New major risk - Financial position

Arctic Bioscience Announces New Positive Data Showing Anti-Inflammatory Effects of Phospholipid Esters from Herring Roe in Immune Cells

Full year 2023 earnings released: kr1.79 loss per share (vs kr1.39 loss in FY 2022)

Full year 2023 earnings released

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

New major risk - Revenue and earnings growth

Arctic Bioscience Announces Recruitment Completed in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS to Report Fiscal Year 2023 Results on Apr 09, 2024

Arctic Bioscience Announces More Than 75% Recruitment in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

New minor risk - Financial data availability

Arctic Bioscience AS Provides Earnings Guidance for the Year 2023

Arctic Bioscience as Announces Operational Update - Heropa Clinical Trial Approved in All 5 Countries and Ongoing

Full year 2022 earnings released

Global Medical Director recently bought €15k worth of stock

Chief Executive Officer recently bought €28k worth of stock

Arctic Bioscience AS (OB:ABS) acquired Arctic Algae As from Ronja Capital II AS for enterprise value NOK 16.3 million.

Arctic Bioscience Announces First Patient Included in HRO350 Phase IIb Clinical Trial in the UK

Arctic Bioscience Announces Clinical Trial Application for HRO350 Phase IIb Approves in UK

Arctic Bioscience AS to Report Fiscal Year 2022 Results on Mar 29, 2023

Less than half of directors are independent

Arctic Bioscience as Maintains Earnings Guidance for the Year 2022

Arctic Bioscience Submits Clinical Trial Application for Hro350 Phase IIb

Arctic Bioscience AS Announces Update on Clinical Trial Application for HRO350 Phase IIb

Arctic Bioscience as Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Full year 2021 earnings released

Arctic Bioscience Provides Earnings Guidance for the Fiscal Year 2022

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Arctic Bioscience AS Provides Earnings Guidance for the Year 2021

Arctic Bioscience Receives Grant from the Research Council of Norway for Its Pharmaceutical Development

Arctic Bioscience Provides Financial Guidance for the Fiscal Year 2021

Arctic Bioscience Signs 3-Year Agreement Worth 75 Million NOK with Smerud Medical Research International to Conduct Clinical Study on Psoriasis

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age